


OVERVIEW PRESS RELEASES **EVENTS & PRESENTATIONS** CORPORATE GOVERNANCE MANAGEMENT BOARD OF DIRECTORS COMMITTEE COMPOSITION CONTACT THE BOARD FINANCIAL INFORMATION SEC FILINGS ANNUAL REPORTS QUARTERLY RESULTS STOCK INFORMATION HISTORIC STOCK LOOKUP INVESTMENT CALCULATOR ANALYST COVERAGE INVESTOR FAQS CONTACT US EMAIL ALERTS



Investor Relations

Melinta Therapeutics, Inc. is dedicated to saving lives threatened by the global public health crisis of bacterial infections, through the development and commercialization of novel antibiotics that provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use

CONTAGIOUS ideas

To Drive Therapy Compliance

in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this pipeline provides Melinta with the unique ability to provide doctors and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.

STOCK QUOTE


Price Change High

Apr 21, 2018 9:44 AM EDT

VIEW DETAILS

Copyright Nasdaq. Minimum 15 minutes delayed.

STOCK CHART



PRESS RELEASES

April 16,
2018

Melinta Therapeutics to Present Detailed
Results from Vabomere TANGO II Trial as well
as New In Vitro and In Vivo Findings from
Baxdela and Pyrrolocytosine Candidate at
ECCMID 2018

March 14, Melinta Therapeutics to Present at Needham
2018
& Company's 17th Annual Healthcare
Conference

March 13, Melinta Therapeutics Cancels Presentation at
2018
The Cowen & Company 38th Annual Health
Care Conference Due to Inclement Weather

EVENTS & PRESENTATIONS

FILTER

RESET

CLICK HERE FOR WEBCAST

Mar 13, 2018

Melinta Therapeutics Q4 2017 Earnings Call

CLICK HERE FOR WEBCAST

Jan 10, 2018

Melinta Therapeutics, Inc. at the 2018 JP Morgan Healthcare Conference Presentation

CLICK HERE FOR WEBCAST

2018 JP Morgan Healthcare Conference Presentation 1.1 MB











Melinta Therapeutics, Inc. ©2018 ALL RIGHTS RESERVED | Terms of Use